FB Pixel no scriptBiotechnology | KrASIA
MENU
KrASIA

Biotechnology

Features

After years of “sleep,” Bloomage faces biotech’s hard realities with a bet on science

Chair Zhao Yan is steering the company away from hype-driven marketing, investing in synthetic biology to rebuild growth and credibility.

9 mins read
  • After inking an USD 8.4 billion deal with BMS, the founder says Biokin’s next chapter is about efficiency, innovation, and going global.

    Features

    The “richest man on the STAR Market” wants more than wealth: Biokin’s chairman sets sights on MNC status

    11 mins read

Most Recent

See All